BioCryst Pharmaceuticals is trading at $9.20, -7.63%, with no clear company-specific catalyst identified for September 8, 2026.
- The latest announcement was a September 1 investor-conference presentation scheduled for September 15, not new earnings, regulatory, or clinical news.
- The broader market is mixed, so the decline cannot be confidently attributed to market-wide selling.